Suppr超能文献

对于接受蒽环类药物和环磷酰胺治疗的癌症患者,在第二天后将5毫克奥氮平添加到阿瑞匹坦、帕洛诺司琼和减少地塞米松用量方案中的止吐疗效。

Antiemetic Efficacy of Adding Olanzapine 5 mg to Aprepitant, Palonosetron and Dexamethasone-Sparing After Day Two for Cancer Patients Receiving Anthracycline and Cyclophosphamide.

作者信息

Suehiro Marii, Kojima Yasuyuki, Takahashi Masaki, Ito Yuka, Keira Takayuki, Ikegawa Kiwako, Minatogawa Hiroko, Tsugawa Koichiro, Tanaka Tsuneaki

机构信息

Department of Pharmacy, St. Marianna University School of Medicine Hospital, Kawasaki-shi, Kanagawa, 216-8511, Japan.

Division of Breast and Endocrine Surgery, Department of Surgery, St. Marianna University School of Medicine Hospital, Kawasaki-shi, Kanagawa, 216-8511, Japan.

出版信息

Cancer Manag Res. 2021 Feb 17;13:1617-1624. doi: 10.2147/CMAR.S280995. eCollection 2021.

Abstract

PURPOSE

Chemotherapy-induced nausea and vomiting (CINV) decrease patient quality of life (QOL). We evaluated the efficacy of adding 5 mg Olz to a three-drug steroid-sparing antiemetic regimen (aprepitant, palonosetron, and dexamethasone-sparing after day two) for breast cancer (BC) patients receiving anthracycline plus cyclophosphamide (AC) chemotherapy.

PATIENTS AND METHODS

We retrospectively reviewed the records of 177 BC patients with no previous highly emetogenic chemotherapy history receiving AC plus the steroid-sparing three-drug regimen or the steroid-sparing four-drug regimen including Olz 5mg at our hospital between January 2012 and December 2018. The primary endpoint was complete response (CR), defined as no vomiting and no usage of rescue medication during the first AC cycle. We analyzed the odds ratio (OR) of the CR with 95% confidence interval (CI) in the three-drug group against the four-drug group. The OR was adjusted for types of anticancer drugs by the Cochran-Mantel-Haenszel (CMH) test. Secondary endpoints were incidences of nausea, anorexia, fatigue, and somnolence during the first cycle.

RESULTS

Compared to the three-drug group, the four-drug group demonstrated high incidence of no vomiting (71% vs 95%), a similar incidence of no rescue medication usage (50% vs 51%), and a similar CR rate (45% vs 49%). The OR of the CR rate in the three-drug group against the four-drug group after CMH adjustment for drug type was 0.958 (95% CI, 0.46-1.98). Compared to the three-drug group, the four-drug group demonstrated identical incidence of nausea (66%), but lower incidences of anorexia (78% vs 35%) and fatigue (86% vs 73%). The incidence of somnolence in the four-drug group was 49%. We did not have data of somnolence for the three-drug group in the records.

CONCLUSION

Adding 5 mg Olz to the steroid-sparing three-drug combination can reduce vomiting, anorexia, and fatigue, although there was no difference in CR rate.

摘要

目的

化疗引起的恶心和呕吐(CINV)会降低患者的生活质量(QOL)。我们评估了在接受蒽环类药物加环磷酰胺(AC)化疗的乳腺癌(BC)患者中,在三联甾体类药物节省方案(阿瑞匹坦、帕洛诺司琼,第二天后节省地塞米松)基础上加用5mg奥氮平(Olz)的疗效。

患者与方法

我们回顾性分析了2012年1月至2018年12月期间在我院接受AC治疗且既往无高度致吐性化疗史的177例BC患者的记录,这些患者接受了甾体类药物节省三联方案或包括5mg Olz的甾体类药物节省四联方案。主要终点是完全缓解(CR),定义为在第一个AC周期内无呕吐且未使用救援药物。我们分析了三联组与四联组CR的比值比(OR)及95%置信区间(CI)。通过Cochran-Mantel-Haenszel(CMH)检验对OR进行抗癌药物类型调整。次要终点是第一个周期内恶心、厌食、疲劳和嗜睡的发生率。

结果

与三联组相比,四联组无呕吐发生率较高(71%对95%),未使用救援药物的发生率相似(50%对51%),CR率相似(45%对49%)。CMH调整药物类型后,三联组与四联组CR率的OR为0.958(95%CI,0.46 - 1.98)。与三联组相比,四联组恶心发生率相同(66%),但厌食发生率较低(78%对35%),疲劳发生率较低(86%对73%)。四联组嗜睡发生率为49%。记录中三联组无嗜睡数据。

结论

在甾体类药物节省三联方案中加用5mg Olz可减少呕吐、厌食和疲劳,尽管CR率无差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2a9/7898054/5c269f604439/CMAR-13-1617-g0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验